Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor β1-associated osteoblastic changes

Prostate

Volumn 69, Issue 11, 2009, Pages 1222-1234

  Izumi, Kouji ^a   Mizokami, Atsushi ^a   You, Qiang Li ^a   Narimoto, Kazutaka ^a   Sugimoto, Kazuhiro ^a   Kadono, Yoshifumi ^a   Kitagawa, Yasuhide ^a   Konaka, Hiroyuki ^a   Koh, Eitetsu ^a   Keller, Evan T ^b   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Prostate cancer; TGF ; Tranilast

Indexed keywords

OSTEOPONTIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53; TRANILAST; TRANSFORMING GROWTH FACTOR BETA1; ANTHRANILIC ACID DERIVATIVE; ANTIALLERGIC AGENT;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL; CASTRATION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; STROMA CELL; TIBIA; TUMOR GROWTH; ADENOCARCINOMA; ANIMAL; BLOOD; BONE TUMOR; CELL CYCLE; COCULTURE; DISEASE MODEL; DOSE RESPONSE; METABOLISM; MIDDLE AGED; MOUSE MUTANT; OSTEOBLAST; OSTEOSARCOMA; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANIMALS; ANTHRANILIC ACIDS; ANTI-ALLERGIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CASTRATION; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; MICE, SCID; MIDDLE AGED; OSTEOBLASTS; OSTEOSARCOMA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 67650609666     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20975     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000;6:1038-1045.
3. Denis L. Prostate cancer. Primary hormonal treatment. Cancer 1993;71(3 Suppl.):1050-1058.
4. Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999;54(6A Suppl.):30-35.
5. Oh WK. Chemotherapy for patients with advanced prostate carcinoma.Anew option for therapy. Cancer 2000;88(12 Suppl.): 3015-3021.
6. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004;171(2 Pt 1):679-683.
7. Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, Yoshikawa T, Endoh M, Yamanaka Y, Yamamoto T, Satoh Y, Ishida H, Okada K, Takimoto Y. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Urol Int 2005;75:43-49.
8. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, Tsujimoto Y, Takayama H, Aozasa K, Okuyama A. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001;93:1739-1746.
9. Hujanen ES, Terranova VP. Migration of tumor cells to organderived chemoattractants. Cancer Res 1985;45:3517-3521.
10. Cooper CR, Pienta KJ. Cell adhesion and chemotaxis in prostate cancer metastasis to bone: A minireview. Prostate Cancer Prostatic Dis 2000;3:6-12.
11. Baylink DJ, Finkelman RD,Mohan S. Growth factors to stimulate bone formation. J Bone Miner Res 1993;8(2 Suppl.):565-572.
12. Centrella M, Horowitz MC, Wozney JM, McCarthy TL. Transforming growth factor-beta gene family members and bone. Endocr Rev 1994;15:27-39.
13. Roberts AB, Wakefield M. The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci USA 2003;100:8621-8623.
14. Yonou H, Horiguchi Y, Ohno Y, Namiki K, Yoshioka K, Ohori M, Hatano T, Tachibana M. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts. Prostate 2007;67:840-848.
15. Isaji M, Miyata H, Ajisawa Y. Tranilast:A new application in the cardiovascular field as an antiproliferative drug. Cardiovasc Drug Rev 1998;16:288-299.
16. Waf1 and p53. J Clin Endocrinol Metab 2002;87:5610-5617.
17. 2+-permeable channel. Cell Calcium 1997;22:75-82.
18. Yashiro M, Chung YS, Sowa M. Tranilast (N-(3,4-dimethoxycinnamoyl) anthranilic acid) down-regulates the growth of scirrhous gastric cancer. Anticancer Res 1997;17:895-900.
19. Noguchi N, Kawashiri S, Tanaka A, Kato K, Nakaya H. Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma. Oral Oncol 2003;39:240-247.
20. Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 2005;65:8818-8825.
21. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, Keller ET. Osteoblasts induce prostate cancer proliferation and PSA expression through inderleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 2004;21:399-408.
22. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-1244.
23. Gerstenfeld LC. Osteopontin in skeletal tissue homeostasis. An emerging picture of the autocrine/paracrine functions of the extracellular matrix. J Bone Miner Res 1999;14:850-855.
24. Morgan DO. Principles of CDK regulation. Nature 1995;374: 131-134.
25. Peter M, Herskowitz I. Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1994;79:181-184.
26. Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J, Weller M. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness ofhumanmalignant glioma cells. Int J Cancer 2001;93:53-61.
27. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, Yandell DW,Weichselbaum RR. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991;46:31-36.
28. Ray S, Shyam S, Almasan A. S-phace checkpoints regulate Apo2 lagand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Mol Cancer Ther 2007;6:1368-1378.
29. Cuptin JF, Cotter TG. Live and let die: Regulatory mechanisms in Fas-mediated apoptosis. Cell Signal 2003;15:983-992.
30. Blaszczyk N, Masri BA, Mawji NR, Ueda T, McAlinden G, Duncan CP, Bruchovsky N, Schweikert HU, Schnabel D, Jones EC, Sadar MD. Osteoblast-derived factors induce androgenindependent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res 2004; 10:1860-1869.
31. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991; 51:3753-3761.
32. Dallas SL, Zhao S, Cramer SD, Chen Z, Peehl DM, Bonewald LF. Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol 2005;202:361-370.
33. Kassem M, Kveiborg M, Eriksen EF. Production and action of transforming growth factor-beta in human osteoblast cultures: Dependence on cell differentiation and modulation by calcitriol. Eur J Clin Invest 2000;30:429-437.
34. Liu W, Toyosawa S, Furuichi T, Kanatani N, Yoshida C, Liu Y, Himeno M, Narai S, Yamaguchi A, Komori T. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 2001;155:157-166.
35. Frank O, Heim M, Jakob M, Barbero A, Schäfer D, Bendik I, Dick W, Heberer M, Martin I. Real-time quantitative RT-PCR analysis of human bone marrow stromal cells during osteogenic differentiation in vitro. J Cell Biochem 2002;85:737-746.
36. Yashiro M, Murahashi K, Matsuoka T, Nakazawa K, Tanaka H, Osaka H, Koyama T, Ohira M, Chung KH. Tranilast (N-3,4-dimethoxycinamoyl anthranilic acid): A novel inhibitor of invasion-stimulating interaction between gastric cancer cells and orthotopic fibroblasts. Anticancer Res 2003;23:3899-3904.
37. el-Shirbiny AM. Prostatic specific antigen. Adv Clin Chem 1994; 31:99-133.
38. Kusama H, Kikuchi S, Tazawa S, Katsuno K, Baba Y, Zhai YL, Nikaido T, Fujii S. Tranilast inhibits the proliferation of human coronary smooth muscle cell through the activation of p21waf1. Atherosclerosis 1999;143:307-313.
39. Cheng I, Stram DO, Penny KL, Pike M, Le Marchand L, Kolonel LN, Hirschhorn J, Altshuler D, Henderson BE, Freedman ML. Commongenetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. J Natl Cancer Inst 2006;18:123-134.
40. Fan J, Stanfield J, Guo Y, Karam JA, Frenkel E, Sun X, Hsieh JT. Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer. Clin Cancer Res 2008;15:1200-1207.